191 related articles for article (PubMed ID: 12652356)
1. The role of oral antidiabetic agents: why and when to use an early-phase insulin secretion agent in Type II diabetes mellitus.
Standl E; Füchtenbusch M
Diabetologia; 2003 Mar; 46 Suppl 1():M30-6. PubMed ID: 12652356
[TBL] [Abstract][Full Text] [Related]
2. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
3. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
4. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
Campbell IW
Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
[TBL] [Abstract][Full Text] [Related]
5. Type II diabetes mellitus.
Edelman SV
Adv Intern Med; 1998; 43():449-500. PubMed ID: 9506190
[TBL] [Abstract][Full Text] [Related]
6. Rationale and options for combination therapy in the treatment of Type 2 diabetes.
Van Gaal LF; De Leeuw IH
Diabetologia; 2003 Mar; 46 Suppl 1():M44-50. PubMed ID: 12652358
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacological treatment of postprandial hyperglycemia].
Blickle JF
Diabetes Metab; 2000 Jun; 26 Suppl 2():20-4. PubMed ID: 10975046
[TBL] [Abstract][Full Text] [Related]
8. Promising new approaches.
Reasner CA
Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
[TBL] [Abstract][Full Text] [Related]
9. The importance of early insulin secretion and its impact on glycaemic regulation.
Garber AJ
Int J Obes Relat Metab Disord; 2000 Sep; 24 Suppl 3():S32-7. PubMed ID: 11063282
[TBL] [Abstract][Full Text] [Related]
10. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs.
Lankisch MR; Ferlinz KC; Leahy JL; Scherbaum WA;
Diabetes Obes Metab; 2008 Dec; 10(12):1178-85. PubMed ID: 19040645
[TBL] [Abstract][Full Text] [Related]
11. Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes.
Raskin P
Diabetes Obes Metab; 2008 Dec; 10(12):1167-77. PubMed ID: 18494804
[TBL] [Abstract][Full Text] [Related]
12. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes.
Thomsen RW; Baggesen LM; Søgaard M; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
Diabetologia; 2015 Oct; 58(10):2247-53. PubMed ID: 26277380
[TBL] [Abstract][Full Text] [Related]
13. Impact of insulin sensitivity, beta-cell function and glycaemic control on initiation of second-line glucose-lowering treatment in newly diagnosed type 2 diabetes.
Rathmann W; Strassburger K; Bongaerts B; Bobrov P; Kuss O; Müssig K; Markgraf DF; Szendroedi J; Herder C; Roden M;
Diabetes Obes Metab; 2017 Jun; 19(6):866-873. PubMed ID: 28127851
[TBL] [Abstract][Full Text] [Related]
14. Gycemic control, mealtime glucose excursions, and diabetic complications in type 2 diabetes mellitus.
Palumbo PJ
Mayo Clin Proc; 2001 Jun; 76(6):609-18. PubMed ID: 11393500
[TBL] [Abstract][Full Text] [Related]
15. The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus.
Del Prato S; Tiengo A
Diabetes Metab Res Rev; 2001; 17(3):164-74. PubMed ID: 11424229
[TBL] [Abstract][Full Text] [Related]
16. Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes.
Hollingdal M; Sturis J; Gall MA; Damsbo P; Pincus S; Veldhuis JD; Pørksen N; Schmitz O; Juhl CB
Diabet Med; 2005 Oct; 22(10):1408-13. PubMed ID: 16176204
[TBL] [Abstract][Full Text] [Related]
17. Early-phase prandial insulin secretion: its role in the pathogenesis of type 2 diabetes mellitus and its modulation by repaglinide.
Owens DR; Cozma LS; Luzio SD
Diabetes Nutr Metab; 2002 Dec; 15(6 Suppl):19-27. PubMed ID: 12702004
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent.
McLeod JF
Clin Pharmacokinet; 2004; 43(2):97-120. PubMed ID: 14748619
[TBL] [Abstract][Full Text] [Related]
19. Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review.
Johansen OE; Birkeland KI
Am J Cardiovasc Drugs; 2007; 7(5):319-35. PubMed ID: 17953471
[TBL] [Abstract][Full Text] [Related]
20. The pathophysiological basis for intensive insulin replacement.
Rolla A
Int J Obes Relat Metab Disord; 2004 Sep; 28 Suppl 2():S3-7. PubMed ID: 15306831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
